Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

目录号：S2680 中文名称：依鲁替尼

Ibrutinib (PCI-32765) Chemical Structure

CAS No. 936563-96-1

Ibrutinib (PCI-32765)是一种有效的，高选择性的Brutons tyrosine kinase (Btk)抑制剂，无细胞试验中IC50为0.5 nM，对Bmx， CSK， FGR， BRK及HCK适度有效，对EGFR， Yes， ErbB2， JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2226.41 现货
RMB 1392.54 现货
RMB 7922.62 现货
RMB 20229.3 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Ibrutinib (PCI-32765)发表文献439篇：

产品安全说明书

Target Protein Ligand抑制剂选择性比较

生物活性

产品描述 Ibrutinib (PCI-32765)是一种有效的，高选择性的Brutons tyrosine kinase (Btk)抑制剂，无细胞试验中IC50为0.5 nM，对Bmx， CSK， FGR， BRK及HCK适度有效，对EGFR， Yes， ErbB2， JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC。
靶点
BTK [1]
(Cell-free assay)		 BLK [1]
(Cell-free assay)		 Bmx [1]
(Cell-free assay)		 CSK [1]
(Cell-free assay)		 FGR [1]
(Cell-free assay)
0.5 nM 0.5 nM 0.8 nM 2.3 nM 2.3 nM
体外研究

Ibrutinib有效可逆且选择性抑制Btk酶活性。Ibrutinib作用于 BCR 通路激活的 DOHH2细胞系, 抑制Btk自磷酸化, Btk's 生理底物 PLCγ磷酸化, 和更远一点的下游激酶ERK的磷酸化，IC50分别为11 nM, 29 nM 和 13 nM。[1] Ibrutinib作用于慢性淋巴细胞白血病 (CLL) 细胞，诱导细胞毒性，这种作用存在剂量和时间依赖性。此外, Ibrutinib诱导 caspase依赖性细胞死亡通路激活，且在TLR信号后，抑制CLL细胞增殖能力。[2] 最新研究显示Ibrutinib抑制 BCR激活的原代 B细胞增殖,IC50 为8 nM，且抑制 原代单核细胞中TNFα, IL-1β 和 IL-6产量， IC50 分别为2.6 nM, 0.5 nM, 和 3.9 nM。 [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Rec1 cells MULGeY5kfGmxbjDhd5NigQ>? NWPTcoJvOi53IN88US=> NVH1VpBvPiCq MWHJcohq[mm2aX;uJI9nKEy7bjDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iUnXjNUBk\WyuczDheEAzNjVidV2gbY5kfWKjdHXkJIZweiB4IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKG2ndHjv[C=> NXzzRXRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlI5PzdpPkK1NlIzQDd5PD;hQi=>
human WSU-NHL cells NGfrPI9EgXSxdH;4bYPDqGG|c3H5 NFLGToY4OiCq Mly3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gW3NWNU6KTDDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkC5JO69VQ>? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
human SU-DHL6 cells Mn[wR5l1d3SxeHnjxsBie3OjeR?= MUS3NkBp M3u2ZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNWNUSKTE[gZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PEDPxE1w Ml7SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
human DOHH2 cells MYPDfZRwfG:6aXRCpIF{e2G7 MnPPO|IhcA>? NFjlNotEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFV0iKMjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxJO69VS5? NUTQV2xlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 cells MlLuSpVv[3Srb36gZZN{[Xl? NX:4XmxvOSCq M3XtWGlvcGmkaYTpc44hd2ZiTGnOMWEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDh[pRmeiB4MDDtbY5{KGK7IGTSMWZTTVRiQYPzZZktKEmFNUC9NE4zKM7:TT6= NUDMfIlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
human Ramos cells MmLMSpVv[3Srb36gZZN{[Xl? MVixJIg> M{HYSWlvcGmkaYTpc44hd2ZiQoTrJIlvKGi3bXHuJHJidW:|IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhWEyFLXfhcY1iOiCyaH;zdIhwenmuYYTpc44h[XRiVInyNVIyPyCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyxiSVO1NF0yPCCwTT6= MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
human Pfeiffer cells NIjs[5dHfW6ldHnvckBie3OjeR?= MlHGO|IhcA>? MoPJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVIZmcW[oZYKgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MjDuUU4> MkXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
Sf9 cells NV3uPZJ[TnWwY4Tpc44h[XO|YYm= MWqxJIg> MmrETY5pcWKrdHnvckBw\iCqdX3hckBnfWyuLXzlcod1cCCEVFug[ZhxemW|c3XkJIlvKFOoOTDj[YxteyC3c3nu[{BHSU1vU4LjeIll\SCyZYD0bYRmKGG|IIP1ZpN1emG2ZTDh[pRmeiB4MDDtbY5{KGK7IGTSMWZTTVRiQYPzZZnwxIxiSVO1NF0xNjVibl2u NVLaXmJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
Sf9 insect cells M{HZUGZ2dmO2aX;uJIF{e2G7 NGj1UVQ3OCCvaX7z MULJR|UxKD1iMD6wNFA{KM7:TR?= Mo[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN|YoRjJ7MUS2NVM3RC:jPh?=
sf9 cells NHXBd4pHfW6ldHnvckBie3OjeR?= MXTJR|UxKD1iMD6wNFA{KM7:TR?= NFvScFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{Pid-Mke5PVQ4OzZ:L3G+
Sf9 insect cells MnTrSpVv[3Srb36gZZN{[Xl? NInMPZk3OCCvaX7z NV;xV3JzUUN3MDC9JFAvODByM{Sg{txO MlvUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUKxO|UoRjJ5OUGyNVc2RC:jPh?=
Sf9 insect cells M1fLSGZ2dmO2aX;uJIF{e2G7 NGDRd5M3OCCvaX7z NH;R[XhKSzVyIE2gNE4xODB|NDFOwG0> MmDoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{K5OFYoRjJ6NEOyPVQ3RC:jPh?=
Sf9 insect cells NIfxdnZHfW6ldHnvckBie3OjeR?= MkHlOlAhdWmwcx?= NETrZllKSzVyIE2gNE4xODB|NDFOwG0> M1HMXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUW2NFM4Lz5{N{m1OlA{PzxxYU6=
Sf9 cells MlXTSpVv[3Srb36gZZN{[Xl? NIXoPXg3OCCvaX7z Mn\lTWM2OCB;IECuNFAxPCEQvF2= M3r0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEC2NVQ{Lz5|MECwOlE1OzxxYU6=
Sf9 cells MWDGeY5kfGmxbjDhd5NigQ>? M1rjdVYxKG2rboO= NXywbHg2UUN3MDC9JFAvODByNTFOwG0> Ml\hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUi1OFcoRjJzOUW4OVQ4RC:jPh?=
Ramos cells MnS0SpVv[3Srb36gZZN{[Xl? MX6xJIg> MnjlTWM2OCB;IECuNFAxPSEQvF2= NX22U4xTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
Sf9 cells MVjGeY5kfGmxbjDhd5NigQ>? NWfqbJh1PjBibXnudy=> MoG1TWM2OCB;IECuNFAyKM7:TR?= NWrpWWw3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO|c3ODhpPkOwNFc4PjB6PD;hQi=>
Pfeiffer cells MVfDfZRwfG:6aXPpeJkh[XO|YYm= NEDhcms4OiCq NIXMNFJIUTVyIE2gNE4xODJizszN NYXB[JhTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
B cells MlrUSpVv[3Srb36gZZN{[Xl? NIfnXGIyKGh? M2PZeGlEPTBiPTCwMlAxPDZizszN NGmzOok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK5NFk5QCd-M{CyPVA6QDh:L3G+
Sf9 insect cells NXHTeJFMTnWwY4Tpc44h[XO|YYm= NV;0VWpTOiC2bzC2NEBucW6| M13xfGtqKD1iMD6wNFQ5KM7:TR?= NFzt[JQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells MlzxSpVv[3Srb36gZZN{[Xl? MnT4NUBp MnXRTWM2OCB;IECuNFA4PSEQvF2= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
Sf9 insect cells MWnGeY5kfGmxbjDhd5NigQ>? NETGcYk3OCCvaX7z M2DGSWlEPTBiPTCwMlAxQCEQvF2= MnLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
TMD8 cells MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NED1U284OiCq M1vQV2lEPTBiPTCwMlAyKM7:TR?= M1P0VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{G1NFI{Lz5{OUexOVAzOzxxYU6=
CD19+ B cells MmjhSpVv[3Srb36gZZN{[Xl? NIn4b|kyKGh? M3j3d2lEPTBiPTCwMlAyOiEQvF2= M1zFdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEW3PVgzLz5{OUS1O|k5OjxxYU6=
Sf9 insect cells MXTGeY5kfGmxbjDhd5NigQ>? MmC2OlAhdWmwcx?= MWTJR|UxKD1iMD6wNVIh|ryP M37jV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
Ramos cells NGrZXYhHfW6ldHnvckBie3OjeR?= MXuxJIg> MlLVTWM2OCB;IECuNFE1KM7:TR?= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
Sf9 insect cells NULLSZlDTnWwY4Tpc44h[XO|YYm= NYfiboxNOSCq MVPJR|UxKD1iMD6wNVQ1KM7:TR?= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdzNUCyN{c,Ojl5MUWwNlM9N2F-
Sf9 insect cells NWCwPFNrTnWwY4Tpc44h[XO|YYm= MofHOlAhdWmwcx?= NIrjSFJKSzVyIE2gNE4xOTZzIN88US=> NIizN2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlE{Pid-MkmxOFYyOzZ:L3G+
HCC827 cells NWDaPZc2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NWrM[VR5PzJiaB?= M{izdmlEPTBiPTCwMlA{QSEQvF2= NV30W3BuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3N|Q2QDFpPkK4O|M1PThzPD;hQi=>
PC9 cells NHnBU2lHfW6ldHnvckBie3OjeR?= MXG3NkBp NEP1dJlIUTVyIE2gNE4xPSEQvF2= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
Sf9 cells NGL6XZFHfW6ldHnvckBie3OjeR?= NXuzVVBDPjBibXnudy=> MYLJR|UxKD1iMD6xJO69VQ>? MlvSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
H3255 cells M{nQbGZ2dmO2aX;uJIF{e2G7 MVe3NkBp NVnzUJNWT0l3MDC9JFAvOTFizszN MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BaF3 cells MoHCSpVv[3Srb36gZZN{[Xl? M3u2NlczKGh? NGm3b|BIUTVyIE2gNE4yOiEQvF2= M1jFflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkOwOVU{Lz5{Nk[zNFU2OzxxYU6=
BAF3 cells NVHw[m15SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NV;lSIFLPzJiaB?= MXLHTVUxKD1iMD6xNkDPxE1? M4PuUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
Sf9 insect cells MkS1SpVv[3Srb36gZZN{[Xl? MWi2NEBucW6| NGrjSFFKSzVyIE2gNE4yOjNizszN MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Sf9 insect cells Mnz2SpVv[3Srb36gZZN{[Xl? Mnj6OlAhdWmwcx?= NWjZOFRLUUN3MDC9JFAvOTR4IN88US=> NYHWVlBTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
BAF3 cells NFLl[2tHfW6ldHnvckBie3OjeR?= NE\WOlA4OiCq NXTZZno2T0l3MDC9JFAvOTZizszN MoLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
Sf9 cells NUHSTGp7TnWwY4Tpc44h[XO|YYm= MVG2NEBucW6| NE\t[3FKSzVyIE2gNE4zKM7:TR?= NVTxRXNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
MV411 cells NXzpZo5{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYLHTVUxKD1iMD6yOUDPxE1? NF;RcJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
MV4-11 cells MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MWi3NkBp NUW2R|VCT0l3MDC9JFAvOzNizszN MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ|MEW1N{c,OjZ4M{C1OVM9N2F-
MV4-11 cells M3m5TGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 Mm\2O|IhcA>? NUTRc|FDT0l3MDC9JFAvOzNizszN MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
DOHH2 cells M{i5[WN6fG:2b4jpZ4l1gSCjc4PhfS=> MoLUO|IhcA>? M{T6R2dKPTBiPTCwMlQyKM7:TR?= NYrIUWNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
HCC827 cells M2n6fGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NI[4[G86PiCq MoTTSWM2OCB;IECuOFUh|ryP MmTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
SU-DHL6 cells Mk\UR5l1d3SxeHnjbZR6KGG|c3H5 MmOzO|IhcA>? NGS3XIRIUTVyIE2gNE42QCEQvF2= NGXxeGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
M07e cells NHvWZpZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmfRS2k2OCB;IECuOVkh|ryP MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
NCI-H1975 cells NV3nfYhZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NWq0WFRlQTZiaB?= M2D4fWVEPTBiPTCwMlY1KM7:TR?= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
SU-DHL-2 cells M2DHd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV3qdJdNT0l3MDC9JFAvPjRizszN MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
HEK293T cells MX7GeY5kfGmxbjDhd5NigQ>? M33GbVEhcA>? M4LoTWlEPTBiPTCwMlkh|ryP NHjuXXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
Ramos cells NFi5R3BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NWH4b5Z{PzJiaB?= NH25Wo1KSzVyIE2gNE46OiEQvF2= NGiweGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUexOVAzOyd-Mkm3NVUxOjN:L3G+
BA/F3 cells Mnq5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NFzCXnQ4OiCq NFfzU5FKSzVyIE2gNUDPxE1? NEDucmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1PFUzOSd-Mk[yOVg2OjF:L3G+
WSU-NHL cells MX7DfZRwfG:6aXPpeJkh[XO|YYm= NGXpNZc4OiCq MVnHTVUxKD1iMT6wPUDPxE1? M{PXbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
NCI-H1975 cells NW\rc2lHTnWwY4Tpc44h[XO|YYm= MonoO|IhcA>? M{jzfWdKPTBiPTCxMlIh|ryP NIW2[5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NCI-H1975 cells MkHGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M4PZN|czKGh? MV3JR|UxKD1iMT6yO{DPxE1? MmHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
Raji cells NYe5b2dwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MXi0PEBp M1XsOmlEPTBiPTCxMlQ6KM7:TR?= NFHxd2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW2O|I6PSd-Mkm1OlczQTV:L3G+
Pfeiffer cells NWrC[HZDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV7HTVUxKD1iMT62JO69VQ>? M1fWWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
A431 cells NWjkOFJnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MljiPVYhcA>? NFPKfVlGSzVyIE2gNk4{QCEQvF2= MlPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O|UoRjJ6OEWzOVc2RC:jPh?=
BAF3 cells NXnhR3FFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MWm3NkBp MoO4S2k2OCB;IEKuOUDPxE1? M4f2[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
U937 cells MljqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoLFS2k2OCB;IEKuPUDPxE1? M4LaXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
NB4 cells MlzSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXTFfodsT0l3MDC9JFMh|ryP MnXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
Ramos cells NXPJcGpPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXXrcm9NT0l3MDC9JFMvPCEQvF2= MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
SKM1 cells M4SxNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVjHNo5rT0l3MDC9JFMvPiEQvF2= NFu3epk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
U2932 cells MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmLSS2k2OCB;IESuOEDPxE1? MlGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
Ramos cells MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? M1v6fVczKGh? M2G2VmlEPTBiPTC1MlE1KM7:TR?= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNkG0N{c,OzByME[xOFM9N2F-
Ramos cells M4npS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MmW1OFghcA>? M4SxemlEPTBiPTC1MlE1KM7:TR?= NETB[Zk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m1OlA{Pyd-Mke5OVYxOzd:L3G+
Ramos cells Mmm3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M2rvSlQ5KGh? Mlr3TWM2OCB;IEWuPFgh|ryP NVvU[I9ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N|I6PDZpPkK4OFMzQTR4PD;hQi=>
Ramos cells NICyZoFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NVPHOphKPzJiaB?= NVr2PWpNUUN3MDC9JFYvPjJizszN MnzRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN|YoRjJ7MUS2NVM3RC:jPh?=
K562 cells MmPDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MW[0PEBp MnvlTWM2OCB;IEeuOUDPxE1? NUHU[JM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO|c3ODhpPkOwNFc4PjB6PD;hQi=>
HL60 cells MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? M4rTdVQ5KGh? NHnZdHVKSzVyIE2gPEDPxE1? M4PESlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEe3OlA5Lz5|MEC3O|YxQDxxYU6=
Ramos cells NI\ZNGVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MXq0PEBp M{fpU2lEPTBiPTC4MlEyKM7:TR?= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOkc,Ojd7OUS3N|Y9N2F-
Ramos cells M33vcmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MVq0PEBp MWXJR|UxKD1iOD6yOkDPxE1? M3WwcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NU[3Nlk2Lz5{OUW2O|I6PTxxYU6=
OCI-AML3 cells MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXfYW5BJT0l3MDC9JFkvOiEQvF2= NHXQeW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
BAF3 cells M2rNeWN6fG:2b4jpZ4l1gSCjc4PhfS=> MV:3NkBp NHjLVndIUTVyIE2gNVAh|ryP NU[wTHRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2N|A2PTNpPkK2OlMxPTV|PD;hQi=>
BAF3 cells NF3aRllCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= Ml60O|IhcA>? MnzuS2k2OCB;IEGwJO69VQ>? Mmq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3 cells MkPzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXK3NkBp NHX1fVZIUTVyIE2gNVAh|ryP M3TpU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NAMALWA cells Ml20RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NG\OWWc4OiCq NHHtPVJKSzVyIE2gNVAvPDVizszN MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN|Y9N2F-
Ramos cells M2nrcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MU[0PEBp MlzQTWM2OCB;IEGyMlYh|ryP MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzMkG3OUc,Ojd7MUKxO|U9N2F-
Raji cells M{H5TWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MlHBOFghcA>? MXHJR|UxKD1iMUSuNkDPxE1? NED1SVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC3O|YxQCd-M{CwO|c3ODh:L3G+
Raji cells Ml3wRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NGDoTG41QCCq M1SxSGlEPTBiPTCxOU4zKM7:TR?= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOkc,Ojd7OUS3N|Y9N2F-
MIAPaCa2 cells MX\DfZRwfG:6aXPpeJkh[XO|YYm= M33VWVMh\GG7cx?= NWXDOVVbUUN3MDC9JFE3NjZizszN NF:xb4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C3O|IzQCd-MkewO|czOjh:L3G+
HeLa cells NILmVZZEgXSxdH;4bYNqfHliYYPzZZk> NE\zTHk{KGSjeYO= M4jGTmlEPTBiPTCxOk45KM7:TR?= MkThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyN{eyNlgoRjJ5MEe3NlI5RC:jPh?=
Raji cells MlXqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M4KzTFQ5KGh? MoHETWM2OCB;IEG5MlMh|ryP Mny0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUKxO|UoRjJ5OUGyNVc2RC:jPh?=
Raji cells MmnNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MX60PEBp MlzXTWM2OCB;IEG5MlMh|ryP MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|Mkm0Okc,Ojh2M{K5OFY9N2F-
Raji cells M4niO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MUS3NkBp MkDWTWM2OCB;IEG5MlUh|ryP MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNkG0N{c,OzByME[xOFM9N2F-
Raji cells MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MWC0PEBp Mn\STWM2OCB;IEG5MlUh|ryP M4PWTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUW2NFM4Lz5{N{m1OlA{PzxxYU6=
NAMALWA cells MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NITObpY4OiCq NV7Efmc5UUN3MDC9JFE6NjZizszN MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNkG0N{c,OzByME[xOFM9N2F-
A2780 cells MV;DfZRwfG:6aXPpeJkh[XO|YYm= MkjsN{Bl[Xm| M3Xve2VEPTBiPTCyNE4yKM7:TR?= NHixRoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C3O|IzQCd-MkewO|czOjh:L3G+
Raji cells MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NF\JW2s4OiCq MW\JR|UxKD1iMkCuPFgh|ryP M1TyVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
A549 cells M{PxTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MmfpO|IhcA>? NIDPVldKSzVyIE2gNlEvPzlizszN M{f5PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{O0OVgyLz5{OEezOFU5OTxxYU6=
SW480 cells MWTDfZRwfG:6aXPpeJkh[XO|YYm= NFHENHE{KGSjeYO= MXHJR|UxKD1iMkWuOkDPxE1? NVXZcVh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO|czOjhpPkK3NFc4OjJ6PD;hQi=>
Ramos cells MWXDfZRwfG:6aXPpeJkh[XO|YYm= M{\KSFI1KGh? M3P1[mlEPTBiPTCyPE44KM7:TR?= NIf1W3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK3OFY4PSd-MkiyO|Q3PzV:L3G+

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
pEGFR(Tyr1068) / EGFR; 

PubMed: 28061447     


Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment.

pBTK / pPLCγ2 / pAKT / pERK / pJNK; 

PubMed: 23940282     


Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.

28061447 23940282
Immunofluorescence
CD11b; 

PubMed: 30231870     


BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm.

COX-2; 

PubMed: 30231870     


BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies. 

30231870
ELISA
hTNFα; 

PubMed: 26627823     


PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3).

IL-10; 

PubMed: 27792904     


LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.

26627823 27792904
体内研究

Ibrutinib 作用于胶原诱导的关节炎模型，通过抑制B细胞活性，显著降低足肿胀和关节发炎等临床关节炎症状。Ibrutinib 作用于 MRL-Fas(lpr) 狼疮模型 ,降低肾疾病和自身抗体产量。[1] Ibrutinib 每天按25 mg/kg剂量作用于过继转移TCL1 的CLL小鼠模型, 产生短暂的早期淋巴细胞增多症，且延迟CLL 疾病进展。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：

[1]
- 合并

激酶实验:

激酶, 33P-ATP, Ibrutinib, 和底物 [0.2 mg/mL 聚(EY)(4:1)]温育1小时后，使用33P 过滤结合实验测量体外激酶IC50值。
细胞实验：

[2]
- 合并
  • Cell lines: 慢性淋巴细胞白血病 (CLL) 细胞
  • Concentrations: 0.01 μM到100 μM
  • Incubation Time: 48小时
  • Method:

    进行MTT实验测定细胞毒性。细胞(CLL B 细胞或健康志愿者T 细胞或 NK细胞) 和不同浓度 Ibrutinib温育48小时。加入MTT试剂,实验板再温育20小时，然后使用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO，通过分光光度法使用Labsystems 酶标仪，在540 nm处测定吸光值。使用膜联蛋白/PI 流式细胞仪在不同时间点测量细胞活力。使用 Expo-ADC32 软件包分析数据。结果表示为总阳性细胞与对照组之比的百分数。加入100μM Z-VAD检测caspase依赖性凋亡。


    (Only for Reference)
动物实验：

[1]
- 合并
  • Animal Models: MRL-Fas(lpr) 狼疮模型和胶原诱导的关节炎模型
  • Dosages: ≤50 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 88 mg/mL (199.77 mM)
Ethanol 45 mg/mL (102.15 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5% DMSO+30% PEG 300+5% Tween 80+ddH2O
 10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 440.5
化学式

C25H24N6O2
CAS号 936563-96-1
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04665115 Not yet recruiting Drug: Ibrutinib|Other: Quality-of-Life Assessment Asymptomatic COVID-19 Infection Laboratory-Confirmed|B-Cell Neoplasm|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Symptomatic COVID-19 Infection Laboratory-Confirmed|Waldenstrom Macroglobulinemia Academic and Community Cancer Research United|National Cancer Institute (NCI) June 30 2021 Phase 2
NCT04876092 Not yet recruiting Drug: JNJ-67856633|Drug: Ibrutinib Leukemia Lymphocytic Chronic B-Cell|Lymphoma Non-Hodgkin Janssen Research & Development LLC June 11 2021 Phase 1
NCT04514393 Not yet recruiting Drug: Methotrexate|Drug: Ibrutinib|Drug: Temozolomide Primary Central Nervous System Lymphoma|PCNSL|Non Hodgkin Lymphoma Huiqiang Huang|Guangdong 999 Brain Hospital|Nanfang Hospital of Southern Medical University|Xian-Janssen Pharmaceutical Ltd.|Sun Yat-sen University December 1 2020 Phase 2
NCT04560322 Not yet recruiting Drug: Venetoclax|Drug: Obinutuzumab|Drug: Ibrutinib Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma Massachusetts General Hospital|Genentech Inc. September 2020 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    How to reconstitute the compound S2680 for in vivo studies?

  • 回答：

    For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

Selleck产品目录册
Tags: 购买Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)供应商 | 采购Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)价格 | Ibrutinib (PCI-32765)生产 | 订购Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID